Advances in lung cancer organoid research

Abstract

Abstract: Lung cancer has high morbidity and mortality rate. Thus, an efficient pre-clinical model that can serve the translational study is urgently needed. The application of organoid should be compared to existing in vitro and in vivo models under different circumstances. The development of organoids of lung cancer has undergone three stages as tissue-specific stem cell differentiation, mixed cell manipulation, and 2-dimensional cultivation. Now, lung cancer organoid can be developed from samples harvested through surgery, biopsy, and circulating tumor cells, with a wide range of application. This review aims to summarize the historical development and application of lung cancer organoids.

Key words: lung cancer, organoid

CLC Number:

R734.2

JIA Zi-qi, WANG Yan-yu, WANG Ya-dong, BING Zhong-xing, LIANG Nai-xin, LI Shan-qing. Advances in lung cancer organoid research[J]. Basic & Clinical Medicine, 2020, 40(8): 1130-1134.

References

[1] Clevers H. Modeling development and disease with organoids[J]. Cell, 2016, 165: 1586-1597.
[2] Sato T, Vries RG, Snippert HJ, et al. Single lgr5 stem cells build crypt villus structures in vitro without a mesenchymal niche[J]. Nature, 2009, 459: 262.
[3] Weeber F, Van De Wetering M, Hoogstraat M, et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases[J]. Proc Natl Acad Sci U S A, 2015, 112: 13308-13311.
[4] Kodack DP, Farago AF, Dastur A, et al. Primary patient-derived cancer cells and their potential for personalized cancer patient care[J]. Cell Rep, 2017, 21: 3298-3309.
[5] Barkauskas CE, Chung MI, Fioret B, et al. Lung organoids: current uses and future promise[J]. Development, 2017, 144: 986-997.
[6] Kopper O, De Witte CJ, Lohmussaar K, et al. An organoid platform for ovarian cancer captures intra-and interpatient heterogeneity[J]. Nat Med, 2019, 25: 838-849.
[7] Aboulkheyr Es H, Montazeri L, Aref AR, et al. Personalized cancer medicine: an organoid approach[J]. Trends Biotechnol, 2018, 36: 358-371.
[8] Praharaj PP, Bhutia SK, Nagrath S, et al. Circulating tumor cell-derived organoids: current challenges and promises in medical research and precision medicine[J]. Biochim Biophys Acta Rev Cancer, 2018, 1869: 117-127.
[9] Hogan BL, Barkauskas CE, Chapman HA, et al. Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function[J]. Cell Stem Cell, 2014, 15: 123-138.
[10] Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and barrett's epithelium[J]. Gastroenterology, 2011, 141: 1762-1772.
[11] Liu X, Krawczyk E, Suprynowicz FA, et al. Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens[J]. Nature Protocols, 2017, 12: 439.
[12] Zepp JA, Zacharias WJ, Frank DB, et al. Distinct mesenchymal lineages and niches promote epithelial self-renewal and myofibrogenesis in the lung[J]. Cell, 2017, 170: 1134-1148,e1110.
[13] Endo H, Okami J, Okuyama H, et al. Spheroid culture of primary lung cancer cells with neuregulin 1/her3 pathway activation[J]. J Thorac Oncol, 2013, 8: 131-139.
[14] Ostrin EJ, Little DR, Gerner-Mauro KN, et al. β-catenin maintains lung epithelial progenitors after lung specifica-tion[J]. Development, 2018, 145.doi:10.1242/dev.160788.
[15] Xu X, Huang L, Futtner C, et al. The cell of origin and subtype of k-ras-induced lung tumors are modified by notch and sox2[J]. Genes Dev, 2014, 28: 1929-1939.
[16] Mas C, Boda B, Caulfuty M, et al. Antitumour efficacy of the selumetinib and trametinib mek inhibitors in a combined human airway-tumour-stroma lung cancer model[J]. J Biotechnol, 2015, 205: 111-119.
[17] Wilkinson DC, Alva-Ornelas JA, Sucre JMS, et al. Development of a three-dimensional bioengineering techno-logy to generate lung tissue for personalized disease modeling[J]. Stem Cells Transl Med, 2017, 6: 622-633.
[18] Chen H, Matsumoto K, Brockway BL, et al. Airway epithelial progenitors are region specific and show differential responses to bleomycin-induced lung injury[J]. Stem Cells, 2012, 30: 1948-1960.
[19] Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer[J]. Science, 2014, 346: 1480-1486.
[20] Zhang Z, Wang H, Ding Q, et al. Establishment of patient-derived tumor spheroids for non-small cell lung cancer[J]. PLoS One, 2018, 13: e0194016.doi:10.1371/journal.pone.0194016.
[21] Ogawa H, Koyanagi-Aoi M, Otani K, et al. Interleukin-6 blockade attenuates lung cancer tissue construction integrated by cancer stem cells[J]. Sci Rep, 2017, 7: 12317.
[22] Jabs J, Zickgraf FM, Park J, et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations[J]. Mol Syst Biol, 2017, 13: 955.
[23] Hild M, Jaffe AB. Production of 3-D airway organoids from primary human airway basal cells and their use in high-throughput screening[J]. Curr Protoc Stem Cell Biol, 2016, 37. https.//doi.org/10.1002/cpsc.1.